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Abstract: HIV/AIDS (Human immunodeficiency virus/ Acquired immuno deficiency syndrome) is a growing global 
problem, in terms of its incidence and mortality. Patients with HIV/AIDS are living much longer with HAART (Highly 
active antiretroviral therapy) therapy so much so that HIV/AIDS has now become a part of the chronic disease burden, 
like hypertension and diabetes. Patients with HIV/AIDS and symptoms suggestive of cardiac disease represent a 
diagnostic and therapeutic challenge in clinical practice; Cardiologists are more frequently encountering this problem. An 
algorithmic, anatomic approach to diagnosis, localizing disease to the endocardium, myocardium and pericardium can be 
useful. An intimate knowledge of opportunistic infections affecting the heart, effects of HAART therapy and therapy for 
opportunistic infections on the heart is needed to be able to formulate a differential diagnosis. Effects of HAART therapy, 
especially protease inhibitors on lipid and glucose metabolism, and their influence on progression to premature vascular 
disease require consideration. Treatment of cardiac disease, in HIV/AIDS patients can vary from non-HIV patients, based 
on drug interactions, differences in responsiveness, and other factors; and this area requires further research. 
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INTRODUCTION 
  The growing global epidemic of HIV/AIDS has made it 
the fourth leading cause of death worldwide [1]. HIV/AIDS 
represents a growing concern to healthcare workers and 
physicians worldwide with a current estimated prevalence of 
close to 40 million worldwide with HIV/AIDS [1]; and 
approx 1 in 302 or 0.33% or 1.2 million [1] people in the 
United States [2]. Moreover, there is not only an increasing 
incidence of HIV/AIDS, but also greatly improved long term 
survival with HAART therapy in this group of patients [3]. 
  Incidence of opportunistic infections has decreased in the 
HAART era in these patients and also the metabolic effects 
of the Highly Active Anti-Retroviral therapy (HAART), 
especially the protease inhibitors (PI) become more prevalent 
in this patient population. Patients with HIV/AIDS are not 
only on HAART therapy, but also on prophylaxis for 
opportunistic infections, depending on their level of immu-
nity competence and prior infections, thereby complicating 
the picture. 
  All of the above problems contribute to the increasing 
sub-group of patients with HIV/AIDS who have heart 
disease, up to 24 % in one autopsy series [4]. Heart disease 
in HIV/AIDS patients poses numerous diagnostic and 
therapeutic challenges; challenges that are unique to this 
population. Of particular importance to cardiologists 
nationwide is the increasing numbers of patients referred by 
internists for a cardiac work up for patients with HIV. 
Hence, in this review article, we aim to provide an overview  
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of the cardiac manifestations of HIV/AIDS, including an 
algorithmic approach, intended for the practicing 
cardiologist. 
  This review article focuses on an anatomic rather than 
etiologic (see Table 1) classification of heart disease in 
patients with HIV/AIDS. The three broad categories are 
pericardial disease, myocardial disease and endocardial 
disease. The fourth category includes arrhythmias, coronary 
artery disease, vascular disease, aneurysmal disease and 
pulmonary hypertension. 
Table 1.   Etiology of Cardiac Effects of HIV/AIDS 
HIV directly affecting the heart 
Opportunistic infections or treatment/prophylaxis of opportunistic 
infections  
Effects of HAART on the Heart  
Non-HIV cardiac risk factors (such as Diabetes Mellitus or 
Hypertension) 
Mode of acquisition of HIV (Intravenous drug use related complications) 
 
  The etiology for each of the above type of heart disease 
in patients with HIV/AIDS is summarized in Table 1. 
In addition, a number of cardiac medications used for 
treatment of various cardiovascular conditions like 
arrhythmias and coronary artery disease interact with anti-
retroviral therapy and an intimate knowledge of drug- drug 
interactions are needed in these patients (see Table 2). 
CARDIAC DISEASE IN PATIENTS WITH HIV/AIDS 
Pericardial Disease 
  Diseases of the pericardium seen in patients with 
HIV/AIDS include pericarditis and pericardial effusions. 150     Current Cardiology Reviews, 2009, Vol. 5, No. 2  Gopal et al. 
Pericarditis in this patient population can result from 
bacterial pericarditis with tuberculosis being the most 
common, Kaposi’s sarcoma [5] or lymphomas [6]. These 
patients can also present with pericardial effusions, but very 
large effusions causing tamponade is rare. Up to 20 % of 
patients with AIDS have been shown to have pericardial 
effusions by echocardiography, and 4 % had large effusions 
[7]. Tuberculosis infrequently affects the pericardium, and is 
less common in developed countries, especially in the United 
States. Pericardial effusions, in patients with HIV/AIDS, 
even without tamponade, frequently require pericardio-
centesis, since the etiology can be varied, and treatment 
depends on the specific etiology [8]. The only caveat of 
pericardiocentesis, in these patients, is the poor diagnostic 
yield for tuberculous pericarditis. In this setting, especially 
with a negative tuberculin skin test, pericardial biopsy may 
be more sensitive in the diagnosis. Treatment of tuberculous 
pericarditis requires special attention; includes anti-
tuberculous therapy and corticosteroids [9, 10]. Empiric anti-
tuberculous treatment should be considered in AIDS patients 
with undiagnosed pericardial effusions. Addition of steroids 
has been shown to have a significant mortality benefit in 
these patients [11]. And the tuberculous effusions may 
sometimes require pericardial fenestration. Presence of 
pericardial disease is a marker of poor prognosis in patients 
with AIDS [7]. 
Myocardial Disease 
  Diseases of the myocardium in patients with HIV/AIDS 
include cardiomyopathy, myocarditis, cardiac tumors and 
drug toxicity.  
  Left ventricular dysfunction associated with HIV/AIDS 
patients is most often clinically silent, and can progress to 
symptomatic left heart failure. The rate of progression from 
left ventricular dysfunction to heart failure can be 
considerably slowed by HAART therapy [12]. The 
pathogenesis of HIV- associated cardiomyopathy is 
exceedingly complex, and includes direct effects of the HIV 
virus on the heart [13], the inflammatory response of the host 
myocardium to the virus [14] and the presence of auto 
antibodies [13], as well as decreased immunity that makes 
them prone to infection. The myocardium lacks CD4 
receptors and since this receptor is the portal of entry of HIV 
into the cell, the virus requires injury to the cardiac myocyte 
by other viruses as a pre-requisite for entry. 
  Myocarditis in HIV/AIDS patients is common, but 
identification of a specific cause can be difficult; only 20 % 
of myocarditis can be attributed to specific causes in 
HIV/AIDS patients. Causes of myocarditis can be extremely 
varied; and can vary from fungal-candidiasis, histoplas-
mosis, cryptococcosis, aspergillosis, viral-herpes simplex, 
cytomegalovirus, bacterial-tuberculosis or parasitic- toxo-
plasmosis [15]. Evaluation should include toxoplasma sero-
logy since it is a potentially treatable cause of myocarditis/ 
cardiomyopathy in these patients. Added to the already long 
list is the fact that the HIV virus by itself can cause 
myocarditis. Drug use- cocaine and methamphetamine 
contributes to cardiac toxicity. Recently, selenium deficiency 
has been shown to be associated with cardiomyopathy [11, 
16]. Reconstitution of the immune system by anti-retroviral 
therapy has been shown to trigger autoimmune responses 
that can contribute to myocardial dysfunction [17, 18]. 
  Cardiac tumors affecting the heart in patients with 
HIV/AIDS are more frequently secondary than primary, as 
in the general population. Kaposi’s sarcoma is usually a part 
of disseminated mucocutaneous involvement, only rarely is 
the heart the sole site of involvement. Lesions are frequently 
asymptomatic. Lymphomas can affect the heart; lymphomas 
in patients with HIV/AIDS are predominantly non-
Hodgkin’s [19]- they can be secondary or primary, the 
former being much more common than the latter. Primary 
Non-Hodgkin’s lymphoma originating in the heart is 
exceedingly rare. Primary cardiac lymphomas, usually B-cell 
lymphomas usually involve the right atrium, and can present 
with conduction disturbances, secondary to infiltration of the 
conduction system [20], arrythmias, superior vena cava 
obstruction or heart failure. Chemotherapy and radiation 
therapy have shown mixed results in these patients [21-23].  
  Drug toxicity can cause clinically significant myocardial 
dysfunction; drugs specific to the HIV/AIDS patients that 
can cause heart failure include zidovudine [24], interferon 
alpha, foscarnet, doxorubicin, pentamidine and amphotericin 
B. 
Endocardial Disease 
  Endocardial/ valvular disease in patients with HIV/AIDS 
can be secondary to bacterial or non-bacterial (marantic) 
endocarditis [4]. Bacterial endocarditis is usually secondary 
to intravenous drug abuse in this patient population [25], 
making  Staphylococcus aureus and Streptococcus viridans 
the most common organisms and the tricuspid valve, the 
most common valve involved. Unlike in the myocardium, 
the HIV virus does not affect the endocardium directly. Non-
Table  2.    Cardiovascular Drugs Interacting with Antiviral 
Therapy [49] 
Cardiovascular medications that interact with anti-retrovirals 
Dihydropyridine calcium-channel blockers 
Sildenafil 
-Blockers, digoxin, and non-dihydropyridine calcium-channel blockers 
Statins Metabolized by CYP3A4: atorvastatin, lovastatin, simvastatin, 
Not metabolized by CYP3A4: fluvastatin, pravastatin 
Anticoagulants- warfarin, antiarrhythmics- amiodarone, antiplatelets- 
ASA, clopidogrel 
Drugs used in HIV positive individuals that interact with cardiovascular 
drugs 
Protease Inhibitors (PI’s)- some act as substrates, CYP enzyme inhibitor/ 
inducers 
Nucleoside reverse transcriptase inhibitors (NRTI)-some act as 
substrates. CYP enzyme inhibitor/ inducers 
Non-nucleotide reverse transciptase inhibitors (NNRTI)- some act as 
substrates. CYP enzyme inhibitor/ inducers 
Antibiotics- Cotrimoxazole, anti-virals- class of acyclovir, anti-fungals- 
azoles 
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bacterial (marantic) endocarditis is usually clinically silent, 
affects the tricuspid valve and can lead to embolism into the 
pulmonary artery, which is also clinically silent. The CD4 
count has implications on the risk of developing heart 
disease, as well as on the prognosis. Patients with lower CD4 
count, especially less than 200, have a higher risk of 
endocarditis, and more importantly, patients with 
endocarditis and lower CD4 counts have a much poorer 
prognosis [26]. Treatment of infective endocarditis in HIV-
infected patients does not differ from those who are HIV-
negative.  
Others- Arrhythmias, Coronary Artery Disease, 
Vascular Disease, Aneurysmal Disease, Pulmonary 
Hypertension, Venous Thrombosis 
A. Arrhythmias 
  Arrhythmias in patients with HIV/AIDS can be the result 
of drug toxicity or the secondary manifestation of myo-
cardial disease. Pentamidine/ Pyrimethamine and TMP-SMZ 
(Trimethoprim- Sulfamethoxazole) used in the treatment of 
toxoplasmosis and PCP (Pneumocystis jirovecii) pneumonia 
respectively, can cause significant Q-T prolongation, and 
therefore torsades de pointes, that can sometimes be fatal. 29 
% of hospitalized patients had QT prolongation [27] and 
torsades de pointes has been described in the absence of drug 
therapy. Ganciclovir, used in the treatment of CMV 
infections, can cause ventricular tachycardia. As discussed 
above, myocardial disease, including heart failure, and 
myocarditis can cause arrhythmias in patients with 
HIV/AIDS. Interferon alpha therapy can predispose patients 
to develop heart blocks and sudden cardiac death. 
B. Coronary Artery Disease and Vascular Disease 
(Cerebral and Peripheral) 
  On one hand, although HAART therapy slows the 
progression to HIV- associated cardiomyopathy, HAART 
therapy, especially the protease inhibitors, have clinically 
significant effects on metabolism; causing hyperlipidemia, 
insulin resistance, lipodystrophy and hyperglycemia [28-30]. 
Different classes of HAART appear to have varying effects 
on the lipid profile, notably, PIs raising low density 
lipoproteins (LDL) [31, 32] and NNRTIs raising HDL 
cholesterol [31]. Accelerated atherosclerosis appears to be 
one of the unexpected side-effects of HAART. The 
relationship between anti-retroviral therapy and coronary 
artery disease is a topic of much debate and uncertainty. 
Suffice, to say, the current literature suggests that HAART 
therapy decreases cardiovascular risk in the short term, but 
prolonged use of HAART therapy, especially protease 
inhibitors has been shown to be associated with increased 
risk of CAD/ MI [28, 33-35]. 
  Patients on HAART therapy have a 26% increased 
relative risk of a myocardial infarction, per year of treatment 
[36]. More recently, it has also been shown that NNRTIs 
have a low to no increased risk of myocardial infarction 
compared to protease inhibitors [37]. It has also been shown 
that Ritonavir, protease inhibitors, is associated with increase 
in carotid intimal wall thickness [38]. The incidence of 
peripheral arterial disease appears to be increased in this 
patient population, independent of traditional cardiovascular  
 
risk factors. Atherosclerosis and vascular disease in patients 
with HIV/AIDS and HAART is a topic of great interest and 
a complete discussion of this topic is beyond the scope of 
this article. 
C. Aneurysmal Disease 
  Patients with HIV/AIDS are more predisposed to 
aneurysmal disease, especially that of the aortic and cerebral 
blood vessels; at a higher incidence than the general 
population. Aneurysms can be due to vasculitis, either by the 
HIV virus itself [39] or secondary infections with CMV or 
tuberculosis [35]. The aneurysms are usually atypical and 
multiple when caused by the HIV virus itself. 
D. Pulmonary Hypertension 
  Patients with HIV/AIDS can develop pulmonary 
hypertension that is believed to be secondary to a 
combination of inflammation and genetic factors [40, 41]. 
Plexogenic arteriopathy has been described in this patient 
population [42, 43]. 
  Primary pulmonary hypertension, occurs in less than 
0.5% of patients with HIV infection [42], the prognosis is 
usually poor. Echocardiography is useful for the diagnosis of 
pulmonary hypertension and to rule out secondary forms. 
Right heart catheterization remains the gold standard for 
diagnosis. Histologically, plexogenic arteriopathy is found 
most commonly, similar to the findings in immunocompetent 
patients [42, 43]. Thrombotic arterial lesions and veno-
occlusive disease occur far more rarely [43]. Intravenous 
drug users are prone to the development of pulmonary 
hypertension, which maybe related to intravenous injection 
of foreign material [44]. This pulmonary hypertension is 
usually worsened by poor compliance [44]. Treatment of 
pulmonary hypertension includes calcium-channel blockers, 
diuretics, anticoagulation, and prostacyclin analogues [45]. 
The latter, specifically epoprostenol, efficiently reduces 
pulmonary artery pressure both acutely and in the long term 
in patients with HIV infection [46]. The effect of HAART 
therapy on slowing the progression of pulmonary 
hypertension is a topic of current research. Zuber et al. 
showed improvement of pulmonary arterial pressures with 
long term HAART therapy [42]. Pulmonary hypertension, 
associated with HIV/AIDS, differs from idiopathic/ primary 
pulmonary hypertension in terms of rapidity of progression, 
is unrelated to CD4 count and is associated with a worse 
prognosis compared to non- AIDS patients. Bosentan/ PDE 
inhibitors and heart-lung transplant are usually the only 
treatment options that work in these sub-groups of patients 
[42]. 
E. Venous Thrombosis 
  The incidence of deep venous thrombosis has been 
shown to be approximately ten times more than the general 
population [47]. The pathogenesis of the prothrombotic state 
appears to be a combination of factors: increase in plasmi-
nogen activator inhibitor (PAI)- type 1, heparin cofactor II, 
protein S and d-dimer values [48]. 
CLINICAL APPROACH TO HEART DISEASE IN 
HIV/AIDS PATIENTS 
  The history and physical examination must be used to 
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patients with HIV/AIDS. The history must include details of 
previous opportunistic infections, traditional risk factors for 
atherosclerosis, details regarding present and prior anti-
retroviral therapy. One of the important questions clinicians 
should ask themselves is whether an HIV-positive individual 
is immunocompetent or immunodeficient- on the basis of a 
recent CD4 count and if not available, this would be 
necessary for further diagnostic evaluation and decisions 
regarding treatment and prognosis (see Fig. (1) for 
algorithm). If the patient is not already on anti-retroviral 
therapy and presents with cardiac symptoms, this may 
require referral to an infectious disease specialist for decision 
making regarding anti-retroviral therapy. Co-ordination of 
care between infectious disease and cardiology can improve 
the quality of care and aid in developing an individualized 
treatment plan based on all of the above factors. Routine use 
of electrocardiography or echocardiography in these patients 
is discouraged, especially because of the lack of evidence for 
finding sub-clinical disease. Shortness of breath is a common 
complaint, and in patients with HIV/AIDS, requires con-
sideration of cardiomyopathy and pulmonary hypertension as 
possible etiologies. Transthoracic echocardiography is 
required for further evaluation. Drug therapy of for heart 
failure is not different from HIV-negative individuals, except 
for consideration of drug-drug interactions, especially with 
anti-retroviral therapy. Endomyocardial biopsy may be 
needed in HIV/AIDS patients with ventricular dysfunction 
on echocardiography to identify potentially treatable causes 
of myocarditis/cardiomyopathy. Lastly, cardiotoxic medica-
tions may need to be stopped in patients who have pre-
existing or those who have developed significant cardiovas-
cular disease. Management of pericardial disease, especially 
tuberculous effusions, is different in this patient population: 
addition of steroids is indicated and pericardiocentesis is 
needed even in the absence of tamponade. Treatment of 
endocarditis does not differ from HIV negative individuals. 
In this new era of significantly improved prognosis in 
patients with HIV/AIDS, both cardiac procedures and 
cardiovascular surgery, including valve replacement and 
coronary artery bypass grafting should be done in these 
patients, except in the setting of advanced immunosuppre-
ssion or high risk of mortality from AIDS- related compli-
cations. Increased incidence of coronary artery disease, 
peripheral vascular disease and deep venous thrombosis has 
been shown in this patient population and requires careful 
consideration of the adverse effects of the different classes of 
anti-retroviral therapy. 
 
Fig. (1). An algorithmic approach to cardiac problems in HIV/AIDS. Heart Disease in Patients with HIV/AIDS  Current Cardiology Reviews, 2009, Vol. 5, No. 2     153 
CONCLUSION 
  A patient with HIV/AIDS and symptoms suggestive of 
cardiac disease, a growing problem, represents a diagnostic 
and therapeutic challenge in clinical practice. An intimate 
knowledge of opportunistic infections affecting the heart, 
effects of HAART therapy and therapy for opportunistic 
infections on the heart need to be considered in the 
differential diagnosis. Effects of HAART therapy, especially 
protease inhibitors on lipid and glucose metabolism, and 
their influence on progression to premature vascular disease 
require consideration. Finally, management of these patients 
can vary from non-infected patients, based on drug 
interactions, differences in responsiveness, and other factors; 
and this area requires further research. 
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